AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33732977 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 922
Study 33732977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 922
Study 33733328 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated brace
Number of subjects: 20
Study 33733443 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone Xen45 gel stent implantation
Number of subjects: 87
Study 33733443 — intervention group
Group type: COMPARATOR
Intervention: Combined procedures with cataract surgery
Number of subjects: 87
Study 33733443 — intervention group
Group type: EXPERIMENTAL
Intervention: Emmetropic eyes (22.0 - 24.5 mm)
Number of subjects: 87
Study 33733657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary DHA intake
Number of subjects: 340
Study 33733980 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil ophthalmic solution 0.02% prescribed once daily
Number of subjects: 261
Study 33733980 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil as monotherapy
Number of subjects: 261
Study 33733980 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil as concomitant therapy
Number of subjects: 261
Study 33734005 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen quantitation of CD20, CD22, CD25, CD19, and %CD38(+) in CLL/SLL and MBL cases by flow cytometry.
Number of subjects: 208
Study 33734088 — intervention group
Group type: EXPERIMENTAL
Intervention: C-IPU (clinic-based multidisciplinary therapy)
Number of subjects: 1090
Study 33734088 — intervention group
Group type: COMPARATOR
Intervention: O-IPU (online integrated multidisciplinary therapy)
Number of subjects: 1090
Study 33734088 — intervention group
Group type: EXPERIMENTAL
Intervention: C-IPU
Number of subjects: 1090
Study 33734088 — intervention group
Group type: COMPARATOR
Intervention: O-IPU
Number of subjects: 1090
Study 33734088 — intervention group
Group type: EXPERIMENTAL
Intervention: Both programs
Number of subjects: 1090
Study 33734135 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir therapy
Number of subjects: 145
Study 33734415 — intervention group
Group type: EXPERIMENTAL
Intervention: cRGDY-PEG-Cy5.5-nanoparticles (2 nmol, 0.4 mL)
Number of subjects: 24
Study 33734415 — intervention group
Group type: COMPARATOR
Intervention: Technetium Tc 99m sulfur colloid (standard-of-care)
Number of subjects: 24
Study 33734415 — intervention group
Group type: EXPERIMENTAL
Intervention: cRGDY-PEG-Cy5.5-nanoparticles
Number of subjects: 24
Study 33734431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional endometrial injury
Number of subjects: 4035
Study 33734431 — intervention group
Group type: COMPARATOR
Intervention: Hysteroscopy with endometrial injury
Number of subjects: 4035
Study 33734431 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial injury in early follicular phase (EFP)
Number of subjects: 4035
Study 33734431 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial injury in late follicular phase (LFP)
Number of subjects: 4035
Study 33734451 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote delivery of family-based therapy
Number of subjects: 0
Study 33735015 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counselling strategies for smoking cessation and risky alcohol consumption
Number of subjects: 0
Study 33735015 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33735176 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell disease (SCD) patients receiving specific treatment
Number of subjects: 872
Study 33735386 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPN group
Number of subjects: 60
Study 33735386 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 33735389 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (200 mg testosterone cypionate injected intramuscularly every 2 weeks for 18 months)
Number of subjects: 105
Study 33735459 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological pupil index (NPi) assessed with a hand-held pupillometer
Number of subjects: 50
Study 33735459 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillary light reflex (PLR)
Number of subjects: 50
Study 33735459 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials (SSEP)
Number of subjects: 50
Study 33735508 — intervention group
Group type: COMPARATOR
Intervention: Dornase alfa
Number of subjects: 2565
Study 33735647 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative symptoms of depression and anxiety
Number of subjects: 370
Study 33735647 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative symptoms of depression
Number of subjects: 370
Study 33736823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ross procedure
Number of subjects: 2444
Study 33737339 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every 3 weeks)
Number of subjects: 615
Study 33737338 — intervention group
Group type: EXPERIMENTAL
Intervention: OAd-MSCs
Number of subjects: 0
Study 33737338 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of OAd-MSCs plus G-CSF
Number of subjects: 0
Study 33737338 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 33737408 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for tuberculosis
Number of subjects: 0
Study 33737431 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative blood transfusions
Number of subjects: 0
Study 33737439 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-like symptoms
Number of subjects: 1490
Study 33737439 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety levels
Number of subjects: 1490
Study 33737439 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 testing
Number of subjects: 1490
Study 33737439 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication changes
Number of subjects: 1490
Study 33737646 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent iron supplement treatment
Number of subjects: 1527
Study 33737646 — intervention group
Group type: EXPERIMENTAL
Intervention: Hb 10.6 g/dL cutoff
Number of subjects: 1527
Study 33737646 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Hb testing between 24 and 30 gestational weeks
Number of subjects: 1527
Study 33737646 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement
Number of subjects: 1527
Study 33737935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rhC1-INH 50 U/kg (maximum, 4,200 U)
Number of subjects: 19
Study 33737935 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment phase (no rhC1-INH)
Number of subjects: 19
Study 33737954 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab beta 150 mg subcutaneously every 4 weeks for up to 5 years
Number of subjects: 0
Study 33737954 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a (from DECIDE study)
Number of subjects: 0
Study 33738451 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 29
Study 33738451 — intervention group
Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 29
Study 33738485 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell trait (HbAS)
Number of subjects: 678
Study 33738485 — intervention group
Group type: COMPARATOR
Intervention: Hemoglobin AA (HbAA)
Number of subjects: 678
Study 33738485 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic parasitemia given infection
Number of subjects: 678
Study 33738485 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 678
Study 33738484 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental pressure to eat
Number of subjects: 148
Study 33738484 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental perceived stress
Number of subjects: 148
Study 33738491 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Ozone Therapy
Number of subjects: 0
Study 33738491 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33738534 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII) - continuous scale
Number of subjects: 3435
Study 33738543 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute alcohol consumption
Number of subjects: 0
Study 33738543 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33738563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative margin assessment using flexible autoradiography (FAR) with ≤ 300 MBq of scintillating film
Number of subjects: 88
Study 33738626 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 3 AMD
Number of subjects: 346
Study 33738626 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of subretinal drusenoid deposits (SDD)
Number of subjects: 346
Study 33738668 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, combined with everolimus.
Number of subjects: 0
Study 33738668 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (doses >5 mg).
Number of subjects: 0
Study 33738774 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla-300
Number of subjects: 46
Study 33738774 — intervention group
Group type: COMPARATOR
Intervention: NPH
Number of subjects: 46
Study 33738776 — intervention group
Group type: EXPERIMENTAL
Intervention: Health economic evaluation for the German healthcare system
Number of subjects: 228
Study 33738776 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal care costs
Number of subjects: 228
Study 33738776 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization costs
Number of subjects: 228
Study 33738776 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct costs
Number of subjects: 228
Study 33738776 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect costs
Number of subjects: 228
Study 33738776 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of the disease
Number of subjects: 228
Study 33738776 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 228
Study 33738776 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs in late stage of the disease
Number of subjects: 228
Study 33738776 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean number of days in hospital and need for care
Number of subjects: 228
Study 33738776 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal caregivers
Number of subjects: 228
Study 33739136 — intervention group
Group type: EXPERIMENTAL
Intervention: Radially adjustable stentrievers
Number of subjects: 0
Study 33739136 — intervention group
Group type: COMPARATOR
Intervention: Standard stentrievers
Number of subjects: 0
Study 33739292 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence program lasting 6 months
Number of subjects: 73
Study 33739292 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence program lasting 12 months
Number of subjects: 73
Study 33739292 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitors and pill counts for assessing medication adherence
Number of subjects: 73
Study 33739292 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equation multimodeling
Number of subjects: 73
Study 33739292 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews for patient satisfaction assessment
Number of subjects: 73
Study 33739295 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant messaging/social media follow-up system
Number of subjects: 15
Study 33739295 — intervention group
Group type: COMPARATOR
Intervention: Telephone interview
Number of subjects: 15
Study 33739857 — intervention group
Group type: EXPERIMENTAL
Intervention: Glofitamab (0.005-30 mg)
Number of subjects: 171
Study 33739956 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care lung ultrasound
Number of subjects: 88
Study 33739956 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care lung ultrasound for bronchiolitis/viral pneumonitis
Number of subjects: 88
Study 33739956 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care lung ultrasound for pneumonia
Number of subjects: 88
Study 33739956 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care lung ultrasound for status asthmaticus
Number of subjects: 88
Study 33740028 — intervention group
Group type: EXPERIMENTAL
Intervention: Lineage B.1 (83.6%)
Number of subjects: 746
Study 33740028 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP C15324T ('Basel cluster')
Number of subjects: 746
Study 33740028 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass gathering event
Number of subjects: 746
Study 33740028 — intervention group
Group type: EXPERIMENTAL
Intervention: Travel returners and family transmissions
Number of subjects: 746
Study 33740028 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis
Number of subjects: 746
Study 33740049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittently scanned continuous glucose monitoring (isCGM)
Number of subjects: 851
Study 33740052 — intervention group
Group type: EXPERIMENTAL
Intervention: Kynurenine:tryptophan ratio at 12 months
Number of subjects: 1169
Study 33740052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol excretion at 6 months
Number of subjects: 1169
Study 33740052 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IGF-1 at 1 month
Number of subjects: 1169
Study 33740205 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of surgery in complete responders to neoadjuvant chemotherapy
Number of subjects: 18
Study 33740205 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary involvement in trial design
Number of subjects: 18
Study 33740205 — intervention group
Group type: EXPERIMENTAL
Intervention: Foundational studies to predict complete pathologic response
Number of subjects: 18
Study 33740420 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive exercise training over 4 weeks
Number of subjects: 0
Study 33740420 — intervention group
Group type: COMPARATOR
Intervention: World-class endurance athletes
Number of subjects: 0
Study 33740734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m² (C20)
Number of subjects: 2131
Study 33740734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m² (C25)
Number of subjects: 2131
Study 33740734 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² (D75)
Number of subjects: 2131
Study 33740734 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (C20, C25, D75)
Number of subjects: 2131
Study 33740885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative driving pressure (ΔP) in open abdominal surgery patients
Number of subjects: 2034
Study 33740885 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative driving pressure (ΔP) in closed abdominal surgery patients
Number of subjects: 2034
Study 33740885 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of postoperative pulmonary complications (PPCs)
Number of subjects: 2034
Study 33740885 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of intraoperative adverse events
Number of subjects: 2034
Study 33740902 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg by 30-min intravenous administration every 12 weeks for up to 8 doses
Number of subjects: 128
Study 33740902 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 128
Study 33740903 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD+ (medicated)
Number of subjects: 45
Study 33740903 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD- (medication-naïve)
Number of subjects: 45
Study 33740903 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 33740918 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise science students
Number of subjects: 993
Study 33740918 — intervention group
Group type: COMPARATOR
Intervention: Reference students
Number of subjects: 993
Study 33741071 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based intervention consisting of an online video and patient recall process for medication reviews.
Number of subjects: 120
Study 33741071 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by GP practices.
Number of subjects: 120
Study 33741070 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based Qigong
Number of subjects: 54
Study 33741070 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Qigong
Number of subjects: 54
Study 33741070 — intervention group
Group type: COMPARATOR
Intervention: Self-care control group
Number of subjects: 54
Study 33741296 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin 1.1 mg/m² in combination with avelumab
Number of subjects: 6
Study 33741296 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (fixed dose)
Number of subjects: 6
Study 33741317 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-062 (100-900 mg)
Number of subjects: 0
Study 33741321 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity
Number of subjects: 216
Study 33741321 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-8 (inflammation marker)
Number of subjects: 216
Study 33741321 — intervention group
Group type: EXPERIMENTAL
Intervention: Total social support
Number of subjects: 216
Study 33741321 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazardous drinking score
Number of subjects: 216
Study 33741402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-frequency transcranial alternating current stimulation (CF-tACS) during cognitive control task performance
Number of subjects: 0
Study 33741402 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33741442 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 8, 10, 12, or 18 mg/kg on days 1 and 8 of 21-day cycles until disease progression or unacceptable toxicity
Number of subjects: 495
Study 33741442 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 495
Study 33741467 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep regional hyperthermia scheduled twice weekly
Number of subjects: 78
Study 33741641 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric per-oral endoscopic myotomy (G-POEM)
Number of subjects: 80
Study 33741670 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical participation in an early phase CAR-T cell therapy trial
Number of subjects: 13
Study 33741689 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 and ABC-AF-bleeding score
Number of subjects: 23718
Study 33741689 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 and ABC-AF-death score
Number of subjects: 23718
Study 33741689 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC-AF-bleeding score
Number of subjects: 23718
Study 33741689 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC-AF-death score
Number of subjects: 23718
Study 33741715 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of EWS-FLI1
Number of subjects: 0
Study 33741715 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of menin
Number of subjects: 0
Study 33741739 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 1030
Study 33742027 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive simulated jogging device (JD) used for 90 minutes per day for 7 days after an initial OGTT (Pre-JD)
Number of subjects: 10
Study 33742027 — intervention group
Group type: COMPARATOR
Intervention: Pre-JD OGTT
Number of subjects: 10
Study 33742027 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-JD OGTT
Number of subjects: 10
Study 33742062 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic clamp to normalize serum glucose
Number of subjects: 23
Study 33742062 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurements in OT2D
Number of subjects: 23
Study 33742104 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor genomic profiling and targeted agents
Number of subjects: 320
Study 33742193 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss Maintainers (WLM)
Number of subjects: 26
Study 33742193 — intervention group
Group type: COMPARATOR
Intervention: Normal Controls (NC)
Number of subjects: 26
Study 33742193 — intervention group
Group type: COMPARATOR
Intervention: Overweight/Obesity Controls (OC)
Number of subjects: 26
Study 33742208 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement with social and behavior change communication intervention
Number of subjects: 367
Study 33742208 — intervention group
Group type: COMPARATOR
Intervention: Comparison district (no intervention)
Number of subjects: 367
Study 33742979 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (IMmotion 010; NCT03024996)
Number of subjects: 5
Study 33742979 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYNOTE-564; NCT03142334)
Number of subjects: 5
Study 33742979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (PROSPER; NCT03055013)
Number of subjects: 5
Study 33742979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with or without ipilimumab (CheckMate 914; NCT03138512)
Number of subjects: 5
Study 33742979 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab with or without tremelimumab (RAMPART; NCT03288532)
Number of subjects: 5
Study 33743073 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic oral vinorelbine (VRL; 30 mg/day)
Number of subjects: 9
Study 33743128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative photodynamic therapy (PDT) after 5-aminolevulinic acid (5-ALA) administration and maximal resection
Number of subjects: 10
Study 33743171 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose P-T (4.5 g every 6 h)
Number of subjects: 40
Study 33743171 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose P-T (up to 6.75 g or 9 g every 6 h)
Number of subjects: 40
Study 33743171 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose P-T
Number of subjects: 40
Study 33743238 — intervention group
Group type: EXPERIMENTAL
Intervention: Onasemnogene abeparvovec (1·1×10^14 vg/kg) administered as a one-time intravenous infusion.
Number of subjects: 22
Study 33743238 — intervention group
Group type: COMPARATOR
Intervention: Untreated PNCR cohort (control group).
Number of subjects: 22
Study 33743477 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia exposure (mean cumulative duration 20.4 h, SD = 15.2, range 0.7-55.6 h)
Number of subjects: 107